• Patients with thrombocytopenia have an increased risk of bleeding. We have used 18 courses of aminocaproic acid in 17 patients with either immune or nonimmune thrombocytopenia to successfully control hemorrhage associated with reduced platelet counts. The types of hemorrhage controlled included the following: vaginal, gastrointestinal, intracerebral, cutaneous, mucous membrane, subconjunctival, and renal, as well as that associated with dental extractions, tracheostomy, and sites of Penrose drains. The number of platelet and red blood cell transfusions administered decreased substantially following institution of aminocaproic acid therapy. We conclude that therapy with aminocaproic acid is safe and useful in the management of bleeding in patients with both immune and nonimmune thrombocytopenia.
(Arch Intern Med. 1989;149:1959-1961)
Bartholomew JR, Salgia R, Bell WR. Control of Bleeding in Patients With Immune and Nonimmune Thrombocytopenia With Aminocaproic Acid. Arch Intern Med. 1989;149(9):1959–1961. doi:10.1001/archinte.1989.00390090039008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.